Business Wire

NTHU

25.11.2021 11:02:06 CET | Business Wire | Press release

Share
A Stitch in Time: Taiwan and Japan Join Hands in Providing Critical Care

Japan has donated five batches of the AZ COVID-19 vaccine to Taiwan, and Taiwan has reciprocated by providing treatment at NTHU’s Boron Neutron Capture Therapy Center (BNCTC) for a 20-year-old Japanese woman suffering from a malignant brain tumor. The treatment was a success, and she has now returned to school.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211125005795/en/

The doctor in charge of the treatment was Yi-Wei Chen of the Oncology Department at Taipei Veterans General Hospital (TVGH). He said that only Taiwan and Japan have medical centers using boron neutron capture therapy (BNCT) to treat cancer. However, Japan’s Ministry of Health, Labor, and Welfare has not yet approved BNCT for treating malignant brain tumors, leaving Taiwan as the only source of treatment for malignant brain tumors that are difficult to treat by surgery.

Chen said that the Japanese patient was originally diagnosed with rhabdomyosarcoma of the right ear canal at the age of six. After surgery and chemotherapy, the condition was stable for a time. Unexpectedly, the tumor recurred in 2018, and the tumor metastasized to the hindbrain. After it was determined that it turned out to be malignant peripheral nerve sheath tumor, she received heavy particle and CyberKnife treatment in Japan, but the tumor still recurred.

Thus she decided to come to Taiwan for BNCT, and arrived in April 2021. By that time the tumor was 6–7 cm in size, but after the first round of irradiation at the THOR BNCT Cancer Center, it shrank by 80%, and the compression on her neck relieved considerably, much to the delight of the medical team, and she returned to Japan. However, at the end of July, some signs of recurrence were discovered, and she was advised to return to Taiwan for a second round of irradiation.

She went to the THOR BNCT Cancer Center for treatment on September 17. After the injection of the Boron-10 drug and a 20-minute session of neutron source irradiation, she had a group photo in front of the NSTDC with the medical team, who presented her with a teddy bear wearing a graduation cap, as a way of wishing her a speedy “graduation” from her cancer. Afterwards, she thanked the medical team in fluent English.

Working closely with the TVGH, the BNCTC has treated over one hundred patients from all over the world, including Spain, Brazil, Australia, Singapore, Japan, and China.

BNCT is a kind of targeted radiotherapy in which the patient is first injected with a boron-containing drug; once the drug has accumulated in the tumor, the neutron beam from the nuclear reactor is used to irradiate the tumor, and the high-energy particles generated by the boron neutron capture reaction effectively kill off the tumor cells, without damaging nearby normal cells. Thus BNCT is well suited for treating diffuse cancers and cases in which surgery is contraindicated.

Social Media:

https://www.facebook.com/nthu.tw

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. Federal Court Permanently Bans 19 Online Sellers of Fake Urolithin A Supplements and Awards $5.3 Million in Damages to Timeline23.7.2026 16:27:00 CEST | Press release

Default judgment follows Timeline’s independent laboratory testing showing products sold under 19 online brands contained no detectable Urolithin A, or far less than advertised Timeline (Amazentis SA), the Swiss life-sciences company that pioneered the postbiotic ingredient Urolithin A and its branded form Mitopure®, together with its U.S. subsidiary Timeline Longevity, Inc., announced today that the U.S. District Court for the District of Massachusetts has granted the companies’ motion for default judgments and permanent injunctions against 19 online sellers found to have marketed and sold nutritional supplements falsely advertised as containing Urolithin A. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722951066/en/ Timeline longevity supplement powered by Mitopure; proprietary, highly pure Urolithin A. The order, entered July 15, 2026 by Judge Myong J. Joun in Amazentis SA et al. v. The Partnerships and Unincorporated

TestMu AI Introduces the Source-to-Verdict Loop in Kane CLI, Carrying Every Requirement to a Ship Decision With Portable Proof23.7.2026 15:45:00 CEST | Press release

Kane CLI now takes a requirement all the way to a ship-or-hold verdict, designing the tests, running them in a real browser, and emitting an open .evidence proof pack that teammates, AI agents, and auditors can all verify, with no server or dashboard required TestMu AI (formerly LambdaTest), the world's first Agentic AI-powered Quality Engineering platform, introduced a source-to-verdict loop in Kane CLI, its natural-language testing tool. Building on Kane CLI's evolution from a browser automation tool, the loop carries a product requirement to a ship decision, writing the tests, running them in the local browser, collecting the proof, measuring coverage from what actually happened, and returning a verdict. As AI agents write, run, and fix tests, a green checkmark is no longer enough: a step that checks nothing passes, a test written against a spec that changed weeks ago passes, and an agent that says “done” without the click ever landing passes. Empty green and earned green are the sa

Norway’s health system adopts Wolters Kluwer UpToDate Enterprise Edition23.7.2026 15:30:00 CEST | Press release

Enterprise Clinical Decision Support solution available to 30,000 clinicians in more than 50 Norwegian hospitals Wolters Kluwer Health announced that Norway’s health system has renewed its adoption of UpToDate Enterprise Edition, a market-leading Clinical Decision Support (CDS) solution, for its nationwide health system which includes over 50 public hospitals and 11,000 beds in over 20 trusts. This extends a 15 year partnership with Helsebiblioteket, now part of the Norwegian Institute of Public Health (NIPH). Helping clinicians on a national scale Kjell Tjensvoll, Team Leader for Helsebiblioteket said, ‘‘Providing frontline teams with easy access to the latest medical knowledge is vital in reducing unwarranted variation and improving patient care on a national scale. UpToDate Enterprise Edition enables this, and we are delighted to strengthen our relationship with Wolters Kluwer and provide continued support for clinicians across the country.’’ UpToDate Enterprise Edition was selected

Boyd Watterson Global Names John Creswell Global Chief Client Officer to Accelerate Global Growth and Client Engagement23.7.2026 15:00:00 CEST | Press release

Veteran investment management executive will lead global sales, client engagement and marketing as Boyd Watterson Global continues expanding its global alternatives platform across real estate, infrastructure, and debt strategies. Boyd Watterson Global today announced the appointment of John Creswell as Global Chief Client Officer, a newly created senior leadership role that reflects the firm's continued investment in growth and its evolution into a leading global alternatives investment platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722823117/en/ John Creswell has joined Boyd Watterson Global as Global Chief Client Officer, a newly created role overseeing global sales, client engagement and marketing across the U.S., Europe and APAC. In this role, Creswell will oversee global sales, client engagement and marketing efforts across the United States, Europe and APAC, helping investors access the firm's capabilitie

Trulioo Launches AI Agent to Resolve Beneficial Ownership Where Global Registries Fall Short23.7.2026 15:00:00 CEST | Press release

Breakthrough AI agent reconstructs ownership for long-tail businesses and hard-to-reach jurisdictions while significantly increasing UBO coverage Trulioo, a global risk intelligence platform, today announced the UBO Discovery Agent, the newest layer in Trulioo's UBO Discovery capability inside its business risk and Know Your Business (KYB) verification workflow. AI is reshaping fraud, making it easier for bad actors to hide, and harder for companies to catch them. This makes the already tough job of verifying who actually owns a business even more difficult. Determining a business's ultimate beneficial owner is an ongoing, acute challenge for companies: registry coverage is inconsistent across countries, and even where registries exist, they typically record shareholders and directors of record (rather than the people actually in control). That data isn't simply outdated, it reflects a structural lag: ownership changes and time passes before the filing is made and processed, so a looku

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye